RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
BLOOD ADVANCES
Collezione AOU Alessandria

Items : 20

Phase 2 study of the lysine-specific demethylase 1 inhibitor bomedemstat for essential thrombocythemia. in Blood advances / Blood Adv. 2026 May 26;10(10):3494-3504. doi: 10.1182/bloodadvances.2025017575.

2026
AOU Alessandria

Gill H; Palandri F; Ross DM; Göthert JR; Cochrane T; Larsen SR; Halpern AB; Shortt J; Rossetti JM; Liang J; Marchetti M; Wilson AJ; Innes AJ; Hanna M; Vianelli N; Stevenson WS; Vannucchi AM; Kleppe M; Flynn J; Natsoulis G; Harrison CN; Rienhoff HY Jr;

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort. in Blood advances / Blood Adv. 2026 Mar 10;10(5):1687-1699. doi: 10.1182/bloodadvances.2025018757.

2026
AOU Alessandria

Gentile M; Gattei V; Morabito F; Tripepi G; Martino EA; Pitino A; Vigna E; Pasquale R; Ferrarini I; Moia R; Visentin A; Sanna A; Motta M; Moratti M; Sportoletti P; Chiarenza A; Maggi A; Zammit V; Merli M; Innocenti I; Giordano C; Nocilli L; Postorino M; Stelitano C; Ferrario A; Frustaci AM; Riva M; Pepe S; Ibatici A; et alii...

No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d-positive CLL mainly expressed in trisomy 12. in Blood advances / Blood Adv. 2026 Jun 9;10(11):3983-3986. doi: 10.1182/bloodadvances.2025018640.

2026
AOU Alessandria

Krampera M; Farina G; Gentile M; Gaidano G; Gattei V; Abbate PL; Quaranta T; Stirparo L; Tomasso A; Autore F; Tissino E; Zucchetto A; Moia R; Martino EA; Giannarelli D; Catania G; Murru R; Moratti M; Pasquale R; Galitzia A; Ferrarini I; Favrin G; Montalbano MC; Vitale C; Mosca A; Guglielmi F; Laurenti L; Visentin A; Innao V; et alii...

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma. in Blood advances / Blood Adv. 2026 Jun 25:bloodadvances.2025018732. doi: 10.1182/bloodadvances.2025018732.

2026
AOU Alessandria

Botto B; Boccomini C; Evangelista A; Zilioli VR; Anastasia A; Cavallo F; Merli F; Zanni M; Tani M; Chiarenza A; Liberati AM; Conconi A; Rusconi C; Bari A; Del Giudice I; Gaidano G; Spina M; Maschio N; Castellino C; Rota-Scalabrini D; Puccini B; Arcari A; Bigliardi S; Matta GME; Bianchi B; Mannina D; Marino D; Galieni P; Ciambelli F; et alii...

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial. in Blood advances / Blood Adv. 2026 Jul 24:bloodadvances.2026020780. doi: 10.1182/bloodadvances.2026020780.

2026
AOU Alessandria

Moia R; Almasri M; Carazzolo ME; Cividini L; Tabanelli V; Melle F; Genuardi E; Cosentino C; Maher N; Bellia M; Mahmoud AM; Evangelista A; Quaglia FM; Fiori S; Bomben R; Tisi MC; Riva M; Merli A; Di Rotondo F; Corradini P; Farina L; Castellino C; Castellino A; Zilioli VR; Muzi C; Piazza F; Re A; Hohaus S; Rossi Dardanoni FG; et alii...

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study. in Blood advances / Blood Adv. 2026 Jul 14;10(13):4585-4594. doi: 10.1182/bloodadvances.2025018141.

2026
AOU Alessandria

Gill H; Yacoub A; Gerds AT; Shortt J; Rossetti JM; Mead AJ; Göthert JR; Koschmieder S; Ewing J; Halpern AB; Palandri F; Passamonti F; Mesa R; Marchetti M; Harrison C; Vannucchi AM; Watts JM; Wood JC; Ross DM; Peppe J; Natsoulis G; Rienhoff HY Jr;

Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study. in Blood advances / Blood Adv. 2026 Jul 14;10(13):4657-4670. doi: 10.1182/bloodadvances.2025018749.

2026
AOU Alessandria

Bruno B; Brunello L; Angelillo P; Farina M; Krampera M; Visco C; Stella F; Petruzzellis G; Crescimanno A; Policastro G; Martino M; Donzelli L; Di Rocco A; Cutini I; Galli E; Tisi MC; Chiappella A; Casadei B; Gabrielli G; Mannina D; Novo M; Grillo G; Argnani L; Bonifazi F; Corradini P; Zinzani PL;

Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial. in Blood advances / Blood Adv. 2025 Apr 22;9(8):1805-1815. doi: 10.1182/bloodadvances.2024014948.

2025
AOU Alessandria
AOU Città della Salute di Torino

Careddu MG; Lucchini E; Patti C; Palmas A; Pascarella A; Michieli M; Vallisa D; Puccini B; Ballerini F; Cavallo F; Stefoni V; Amaducci E; Evangelista A; Civita AM; Alessandria B; Gandossini M; Genuardi E; Galli A; Ragaini S; Merli M; Postorino M; Boccomini C; Balzarotti M; Zilioli VR; Gomes da Silva M; Bruno B; Rizzo E; Ladetto M; Malcovati L; et alii...

IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma. in Blood advances / Blood Adv. 2024 Mar 26;8(6):1541-1549. doi: 10.1182/bloodadvances.2023011251.

2024
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara
ASL Biella

Bonomini L; Vitolo U; Cesaretti M; Esposito F; Pirosa MC; Pinotti G; Dore F; Pisani F; Zanni M; Ghiggi C; Liberati AM; Annibali O; Cabras MG; Celli M; Orsucci L; Tani M; Bruna R; Vanazzi A; Tucci A; Merli F; Balzarotti M; Gaidano G; Sassone M; Zucca E; Botto B; Stathis A; Ferreri AJM; Chiappella A; Conconi A; et alii...

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. in Blood advances / Blood Adv. 2023 Jun 13;7(11):2645-2655. doi: 10.1182/bloodadvances.2022009578.

2023
AOU Alessandria

van Doesum JA; Salmanton-García J; Marchesi F; Di Blasi R; Falces-Romero I; Cabirta A; Farina F; Besson C; Weinbergerová B; Van Praet J; Schönlein M; López-García A; Lamure S; Guidetti A; De Ramón-Sánchez C; Batini? J; Gavriilaki E; Tragiannidis A; Tisi MC; Plantefeve G; Petzer V; Ormazabal-Vélez I; Marques de Almeida J; Marchetti M; Maertens J; Machado M; Kulasekararaj A; Hernández-Rivas JÁ; Gomes da Silva M; et alii...

Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial. in Blood advances / Blood Adv. 2023 Jul 25;7(14):3764-3774. doi: 10.1182/bloodadvances.2022009504.

2023
AOU Alessandria
AOU Città della Salute di Torino

Puccini B; Ferreri AJM; Ballerini F; Lucchini E; Arcaini L; Moita F; Zilioli V; Balzarotti M; Cavallo F; Boccomini C; Stefoni V; Re A; Di Rocco A; Tavarozzi R; Ghislieri M; De Luca G; Genuardi E; Alessandria B; Zaccaria GM; Pironti M; Arrigoni E; Grimaldi D; Ferrero S; Palumbo GA; Galimberti S; Cortelazzo S; Di Paolo A; Ladetto M;

A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma. in Blood advances / Blood Adv. 2023 Aug 8;7(15):4160-4169. doi: 10.1182/bloodadvances.2023009839.

2023
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Spina M; Marcheselli L; Tabanelli V; Mammi C; Bernuzzi P; Cencini E; Ferrero S; Nassi L; Dessì D; Pagani C; Vallisa D; Merli M; Di Rocco A; Tani M; Flenghi L; Hohaus S; Tarantini G; Zanni M; Gini G; Botto B; Sartori R; Marino D; Musuraca G; Mahmoud AM; Pennese E; Zilioli VR; Luminari S; Pelliccia S; Balzarotti M; et alii...

Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL. in Blood advances / Blood Adv. 2023 Aug 8;7(15):3916-3924. doi: 10.1182/bloodadvances.2023009744.

2023
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Merli F; Arcari A; Zilioli VR; Re A; Volpetti S; Stelitano C; Quaglia FM; Pileri SA; Bruna R; Ferrante M; Sciarra R; Zambello R; Zanni M; Di Rocco A; Ghiggi C; Chini C; Cencini E; Celli M; Puccini B; Tani M; Botto B; Spina M; Ferrero S; Evangelista A; Patti C; Moia R; Tisi MC; Visco C;

COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. in Blood advances / Blood Adv. 2022 Jul 12;6(13):3870-3874. doi: 10.1182/bloodadvances.2022007357.

2022
AOU Alessandria
AOU Città della Salute di Torino

Passamonti F; Pagliuca A; Koehler P; Klimko N; Corradini P; Hoenigl M; Busca A; Zompi S; Sacchi MV; Nunes Rodrigues R; Nordlander A; Essame J; Cordoba R; Batini? J; Bergantim R; Bilgin YM; Blennow O; Cattaneo C; Duarte RF; Emarah Z; Gomes da Silva M; González-López TJ; Kulasekararaj A; Ledoux MP; López-García A; Merelli M; Prezioso L; Ilhan O; Seval GC; et alii...

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. in Blood advances / Blood Adv. 2022 Jul 12;6(13):3875-3878. doi: 10.1182/bloodadvances.2022006964.

2022
AOU Alessandria
AOU Città della Salute di Torino

Trentin L; Angeletti I; Coscia M; Patti C; Sanna A; Murru R; Sapienza G; Cuccaro A; Marasca R; Sportoletti P; Morelli F; Chiarenza A; Vitale C; Moretti M; Tomasso A; Visentin A; Catania G; Piciocchi A; Autore F; Fresa A; Pietrasanta D; Innocenti I; Laurenti L;

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. in Blood advances / Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691.

2022
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AOU Novara

Corradini P; Merli F; Passamonti F; Candoni A; Krampera M; Venditti A; Selleri C; Tosi P; Lanza F; Conconi A; La Barbera EO; Gambacorti-Passerini C; Visani G; Vallisa D; Rigacci L; Armiento D; Gherlinzoni F; Tafuri A; Galimberti S; Bocchia M; Corso A; Cilloni D; Cardinali V; Turrini M; Trentin L; Cuneo A; Della Porta M; Massaia M; Fracchiolla N; et alii...

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. in Blood advances / Blood Adv. 2021 Nov 9;5(21):4504-4514. doi: 10.1182/bloodadvances.2021005150.

2021
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Zinzani PL; Ciccone G; Freilone R; Rota-Scalabrini D; Zilioli VR; Botto B; Simontacchi G; Tani M; Zaja F; Abruzzese E; Rigacci L; Santoro A; Pulsoni A; Franzone P; Grapulin L; Nassi L; Frezza GP; Zanni M; Pavone V; Nardella A; Buglione M; Re A; Filippi AR; Gioia DM; Gotti M; Sacchetti GM; Evangelista A; Ricardi U; Levis M; et alii...

Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials. in Blood advances / Blood Adv. 2021 Mar 23;5(6):1737-1745. doi: 10.1182/bloodadvances.2020002724.

2021
AOU Alessandria

Casulo C; Dixon JG; Ou FS; Hoster E; Peterson BA; Hochster HS; Brice P; Ladetto M; Hiddemann W; Marcus R; Kimby E; Herold M; Nielsen T; Morschhauser F; Rummel M; Hagenbeek A; Vitolo U; Salles GA; Shi Q; Flowers CR;

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. in Blood advances / Blood Adv. 2019 Dec 23;3(24):4280-4290. doi: 10.1182/bloodadvances.2019000865.

2019
AOU Alessandria
AOU Città della Salute di Torino
AOU Novara

Soverini S; Vigneri P; Rosti G; Russo D; Saglio G; Castagnetti F; Pane F; Breccia M; Bonifacio M; Tomassetti S; Trabacchi E; Spadano R; Tiribelli M; Stagno F; Sancetta R; Sica S; Rege-Cambrin G; Rupoli S; Salvucci M; Rapezzi D; Pregno P; Palmieri F; Musolino C; Miggiano MC; Montefusco E; Melpignano A; Martino B; Marasca R; Lunghi M; et alii...

Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. in Blood advances / Blood Adv. 2019 Apr 9;3(7):1103-1117. doi: 10.1182/bloodadvances.2018026625.

2019
AOU Alessandria
AOU Città della Salute di Torino

Spinelli O; Oldani E; Zanghì P; Ferrero D; Cortelezzi A; Corradini P; Campiotti L; Todisco E; Scattolin AM; Bernardi M; Borlenghi E; Ciceri F; Cattaneo C; De Paoli L; Terruzzi E; Mattei D; Cavattoni I; Marmont F; Gianfaldoni G; Boschini C; Pavoni C; Masciulli A; Bassan R; Intermesoli T; Audisio E; Cortelazzo S; Bosi A; Falini B; Pogliani EM; et alii...